Testing for hepatitis B infection in prospective chemotherapy patients: A retrospective study

World Journal of Gastroenterology

Volumn 19, Issue 6, 2013, Pages 923-930

  Wang, Ying ^a,b   Luo, Xin Mei ^a,b   Yang, Dan ^a,b   Zhang, Jie ^a,b   Zhuo, Hong Yu ^a,b   Zhang, Jian ^a,b   Jiang, Yu ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Chemotherapy; Hematologic malignancy; Hepatitis B virus; Hepatitis B virus reactivation; Solid tumor

Indexed keywords

AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PREDNISOLONE; RITUXIMAB; VINCRISTINE; VIRUS DNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; FEMALE; GENDER; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; INFECTION RATE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; VIRUS REACTIVATION;

EID: 84873712099     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i6.923     Document Type: Article

References (40)

1. World Health Organization. Hepatitis B: World Health Organization Fact Sheet 204. Available from: URL: http://www.who.int/mediacentre/factsheets/fs204/en/
2. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y. Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009; 27: 6550-6557. [PMID: 19729084 DOI: 10.1016/j.vaccine.2009.08.048]
3. Liu CJ, Chen PJ, Chen DS, Kao JH. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatol Int 2011 Jun 14; Epub ahead of print. [PMID: 21670970 DOI: 10.1007/ s12072-011-9279-6]
4. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307. [PMID: 11055239 DOI: 10.1002/1096-9071(200011)]
5. Manzano-Alonso ML, Castellano-Tortajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol 2011; 17: 1531-1537. [PMID: 21472116 DOI: 10.3748/wjg.v17.i12.]
6. Niitsu N, Hagiwara Y, Tanae K, Kohri M, Takahashi N. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol 2010; 28: 5097-5100 [PMID: 20837949 DOI: 10.1200/JCO.2010.29.7531]
7. Yeo W, Lam KC, Zee B, Chan PS, Mo FK, Ho WM, Wong WL, Leung TW, Chan AT, Ma B, Mok TS, Johnson PJ. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004; 15: 1661-1666. [PMID: 15520068 DOI: 10.1093/annonc/mdh430]
8. Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu CH, Tien HF, Chao TY, Chen LT, Whang-Peng J. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003; 37: 1320-1328. [PMID: 12774010 DOI: 10.1053/jhep.2003.50220]
9. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519-528. [PMID: 18378948]
10. Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, Lam KC, Johnson PJ. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-1311. [PMID: 15054446 DOI: 10.1038/ sj.bjc.6601699]
11. European Association For The Study Of The Liver. EASL clinical practice guidelines. Management of chronic hepatitis B. Gastroenterol Clin Biol 2009; 33: 539-554. [PMID: 19481389 DOI: 10.1016/j.gcb.2009.03.002]
12. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539. [PMID: 17256718 DOI: 10.1002/hep.21513]
13. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, Neitzel SM, Ward JW. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57: 1-20. [PMID: 18802412]
14. Lee R, Vu K, Bell CM, Hicks LK. Screening for hepatitis B surface antigen before chemotherapy: current practice and opportunities for improvement. Curr Oncol 2010; 17: 32-38. [PMID: 21151407]
15. Hwang J, Fisch M, Zhang H, Kallen M, Routbort M, Lal L. S, Vierling J and Suarez-Almazor M. Reactivation of hepatitis B infection among patients with cancer. J Clin Oncol 2011; 29 Suppl 15: 9056.
16. Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2008; 2: 152-162. [PMID: 19669300 DOI: 10.1007/s12072-008-9056-3]
17. Tran TT, Rakoski MO, Martin P, Poordad F. Screening for hepatitis B in chemotherapy patients: survey of current oncology practices. Aliment Pharmacol Ther 2010; 31: 240-246. [PMID: 19814747 DOI: 10.1111/j.1365-2036.2009.04158.x]
18. Khokhar OS, Farhadi A, McGrail L, Lewis JH. Oncologists and hepatitis B: a survey to determine current level of awareness and practice of antiviral prophylaxis to prevent reactivation. Chemotherapy 2009; 55: 69-75. [PMID: 19077421]
19. Hwang J, Fisch M, Zhang H Kallen, M. Routbort, L. Lal, J. Vierling, M. Suarez-Almazor. Hepatitis B screening and positivity prior to chemotherapy. J Clin Oncol 2010; 28 Suppl 15: 9008.
20. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-611. [PMID: 19075267 DOI: 10.1200/JCO.2008.18.0182]
21. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, Cheung M, Zhang HY, Lie A, Ngan R, Liang R. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-1749. [PMID: 14724827 DOI: 10.1053/ j.gastro.2003.09.026]
22. Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, Hou JL, Wen YM, Nanj A, Liang R. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002; 99: 2324-2330. [PMID: 11895763 DOI: 10.1182/blood.V99.7.2324]
23. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 1986; 83: 1627-1631. [PMID: 3006059]
24. Liaw YF. Hepatitis viruses under immunosuppressive agents. J Gastroenterol Hepatol 1998; 13: 14-20. [PMID: 9737566 DOI: 10.1111/j.1440-1746.1998.tb00539.x]
25. Lau GK, He ML, Fong DY, Bartholomeusz A, Au WY, Lie AK, Locarnini S, Liang R. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002; 36: 702-709. [PMID: 12198664]
26. Keam B, Lee JH, Im SA, Yoon JH. Why, when, and how to prevent hepatitis B virus reactivation in cancer patients undergoing chemotherapy. J Natl Compr Canc Netw 2011; 9: 465-477. [PMID: 21550967]
27. Chen XQ, Peng JW, Lin GN, Li M, Xia ZJ. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy. Med Oncol 2012; 29: 1237-1241. [PMID: 21556931 DOI: 10.1007/s12032-011-9974-0]
28. Yeo W, Ho WM, Hui P, Chan PK, Lam KC, Lee JJ, Johnson PJ. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 2004; 88: 209-215. [PMID: 15609123]
29. Zoulim F, Poynard T, Degos F, Slama A, El Hasnaoui A, Blin P, Mercier F, Deny P, Landais P, Parvaz P, Trepo C. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J Viral Hepat 2006; 13: 278-288. [PMID: 16611195 DOI: 10.1111/j.1365-2893.2005.00712.x]
30. Watanabe M, Shibuya A, Takada J, Tanaka Y, Okuwaki Y, Minamino T, Hidaka H, Nakazawa T, Koizumi W. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients. Eur J Intern Med 2010; 21: 333-337. [PMID: 20603047 DOI: 10.1016/j.ejim.2010.04.010]
31. Mimura N, Kojima H, Tsujimura H, Ise M, Sakai C, Fukai K, Yokosuka O, Kumagai K. [Prevention of hepatitis B virus reactivation in B-cell lymphoma patients receiving chemotherapy with rituximab]. Rinsho Ketsueki 2010; 51: 213-215. [PMID: 20379117]
32. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis 2009; 200: 39-47. [PMID: 19469708 DOI: 10.1086/599332]
33. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, Leung N, Luk JM, Lie AK, Kwong YL, Liang R, Lau GK. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68. [PMID: 16831590]
34. Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, Tai DW, Quek R, Tao M, Lim ST. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol 2011; 90: 1219-1223. [PMID: 21520001]
35. Sugauchi F, Tanaka Y, Kusumoto S, Matsuura K, Sugiyama M, Kurbanov F, Ueda R, Mizokami M. Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy. J Med Virol 2011; 83: 412-418. [PMID: 21264861]
36. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002; 2: 479-486. [PMID: 12150847]
37. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007; 46: 160-170. [PMID: 17112622 DOI: 10.1016/j.jhep.2006.10.007]
38. Semnani S, Roshandel G, Abdolahi N, Besharat S, Keshtkar AA, Joshaghani H, Moradi A, Kalavi K, Jabbari A, Kabir MJ, Hosseini SA, Sedaqat SM, Danesh A, Roshandel D. Hepatitis B/C virus co-infection in Iran: a seroepidemiological study. Turk J Gastroenterol 2007; 18: 20-21. [PMID: 17450490]
39. Gaeta GB, Stornaiuolo G, Precone DF, Lobello S, Chiaramonte M, Stroffolini T, Colucci G, Rizzetto M. Epidemiological and clinical burden of chronic hepatitis B virus/ hepatitis C virus infection. A multicenter Italian study. J Hepatol 2003; 39: 1036-1041. [PMID: 14642623 DOI: 10.1016/ S0168-8278(03)00470-7]
40. Raimondo G, Cacciamo G, Saitta C. Hepatitis B virus and hepatitis C virus co-infection: additive players in chronic liver disease? Ann Hepatol 2005; 4: 100-106. [PMID: 16010242]